Oscar Health’s Stock Gets a Second Look—What’s Behind the Buzz?

Oscar Health, a company focused on health insurance under the Affordable Care Act, just got a boost from Barclays. The bank’s analyst upgraded its stock to “Overweight” and set a price target of $35, suggesting shares could jump another 25% soon. That’s a big deal because Oscar’s stock is already up 160% since March—a sharp rise that makes people wonder if the good times will last. One reason Barclays is optimistic is because Oscar’s stock price looks too low compared to similar companies. While competitors trade at high earnings multiples, Oscar is stuck at just 11. 5 times earnings. That gap might not make sense if investors start paying more attention to the ACA market, where Oscar specializes. Some technical indicators also back this up, with over 88% of analysts recommending a buy right now.

But not everyone is convinced. Some experts think Oscar’s stock could actually drop in the next year, even though Barclays sees long-term potential. The average price target from Wall Street is just $22, which is 20% below where shares are now. And unlike many insurance firms, Oscar doesn’t pay dividends, so it doesn’t offer that extra incentive to hold it long-term. The bigger question is whether Oscar can keep growing. Barclays argues that Wall Street’s profit forecasts for 2028 are too low. The company itself expects margins to hit 5%, but analysts currently predict just 3%. If Oscar can prove it can meet its own goals, shares could rise fast. Early signs suggest the market is improving, which might help its pricing power. Still, investors should be careful. The mixed signals mean Oscar isn’t a slam-dunk bet. Some see big upside, while others warn of possible downsides in the short term. Time will tell if the bulls or bears are right.

Actions